Yield10 bioscience, inc. (YTEN)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Cash flows from operating activities
Cash flows from operating activities
Net loss

-12,956

-9,185

-9,396

-7,604

-23,681

-29,534

-30,506

-

-

-

-

Loss from discontinued operations

-

-

-

-

-11,241

-2,766

-1,962

-326

-

-

-

Loss from continuing operations

-

-

-

-

-12,440

-26,768

-28,544

3,956

-

-

-

Net loss

-

-

-

-

-

-

-

3,630

-38,785

-38,803

-37,957

Adjustments to reconcile net loss to cash used in operating activities:
Depreciation

203

196

206

515

265

507

928

1,298

1,507

1,647

2,734

Loss on issuance of securities

-13,018

0

-

-

-

-

-

-

-

-

-

Change in fair value of warrants

-9,541

0

-

-

-

-

-

-

-

-

-

Inventory impairment

-

-

-

199

209

873

746

138

-

-

-

Gain on sale of discontinued operation and property and equipment

-

-

-

9,833

33

43

0

0

-

-

-

Non-cash restructuring expense paid through stock and equipment

-

-

-

196

-

-

-

-

-

-

-

Non-cash restructuring expense paid through stock and equipment

-

-

-

-

0

-

-

-

-

-

-

Loss on disposal of fixed assets

-

-

-

-

-

-

-

-

-

-

70

Charge for 401(k) company common stock match

98

102

85

281

323

374

397

408

529

443

428

Stock-based compensation

656

1,181

1,395

848

2,128

2,276

3,122

3,779

4,633

4,696

4,653

Non-cash lease expense

1,625

588

-

-

-

-

-

-

-

-

-

Deferred tax provision

-254

0

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivables

-22

40

-12

-172

193

-952

158

693

146

-

-

Accounts receivable

-

-

-

-

-

-

-

-

-

-19

-140

Due from related parties

-

-

-1

-145

34

61

-24

-236

71

15

-

Unbilled receivables

-46

1

-56

-

-

-

-

-

-

-

-

Unbilled receivables

-

-

-

-29

-270

223

-185

68

296

5

-53

Inventory

-

-

-

-180

2

-462

516

2,288

-

-

-

Prepaid expenses and other assets

-9

128

-660

-1,302

1,081

43

21

-108

-68

104

205

Accounts payable

162

41

17

-51

-226

-246

-654

721

273

-387

-232

Accrued expenses

502

-1,072

-622

-845

62

-1,179

1,383

-34

-623

329

334

Lease liabilities

-2,244

-436

-

-

-

-

-

-

-

-

-

Proceeds from options exercised

-

-

-

-

-

-

-

-

-

-

116

Proceeds from public stock offerings, net of issuance costs

-

-

13,318

0

-

-

-

-

49,333

-

29,118

Lease liabilities

-

-

-

339

0

-50

-151

-154

-153

-

-

Other long-term liabilities

-

-

-616

-

-

-

-

-

-

-

-

Net cash used in operating activities

-

-

-

-14,404

-21,863

-23,691

-23,657

-30,384

-31,731

-31,995

-25,759

Net cash used by discontinued operations for operating activities

-

-

-

-

-

-845

-2,991

-1,352

-

-

-

Net cash used for operating activities

-8,654

-8,754

-8,202

-

-

-24,536

-26,648

-31,736

-

-

-

Cash flows from investing activities
Cash flows from investing activities
Purchase of property and equipment

61

42

6

752

654

172

373

392

895

906

2,017

Proceeds from sale of property and equipment

-

-

-

10,317

40

43

0

12

-

-

70

Change in restricted cash

-

-

-

-187

0

0

25

-28

-

29

-

Purchase of short-term investments

5,704

11,496

0

-

-

1,508

16,635

58,933

107,477

83,814

119,956

Proceeds from the sale and maturity of short-term investments

2,750

8,750

0

-

-

13,017

36,821

84,303

99,464

116,126

103,048

Net cash provided (used) by continuing operations for investing activities

-

-

-

-

-

11,380

19,788

25,018

-8,908

31,377

-18,855

Net cash provided by discontinued operations for investing activities

-

-

-

-

-

292

0

0

-

-

-

Net cash provided by investing activities

-3,015

-2,788

-6

9,752

-614

11,672

19,788

25,018

-

-

-

Cash flows from financing activities
Proceeds from warrants exercised

0

124

-

-

-

-

-

-

-

-

-

Proceeds from securities offerings, net of issuance costs

14,083

0

-

-

-

-

-

-

-

-

-

Proceeds from warrants exercised

-

-

0

-

-

300

14

19

74

2,339

-

Proceeds from registered direct offering, net of issuance costs

-

-

1,966

0

14,703

24,914

0

0

-

-

-

Deferred rent and other long-term liabilities

-

-

-

-

-

-

-

-

-

-156

-156

Deferred revenue

-

-

-

-277

130

-522

-398

-37,791

1,333

341

4,519

Taxes paid on employees' behalf related to vesting of stock awards

4

6

12

-

0

-

-

-

-

-

-

Net cash provided by financing activities

14,079

118

15,272

-

-

-

-

-

-

-

-

Effect of exchange rate changes on cash, cash equivalents and restricted cash

-16

-25

-1

-

-

-

-

-

-

-

-

Net (decrease) increase in cash, cash equivalents and restricted cash

2,394

-11,449

7,063

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-296

14,703

25,214

14

19

49,407

2,339

29,234

Effect of exchange rate changes on cash, cash equivalents and restricted cash

-

-

-

-12

-3

-2

-28

-6

-17

-9

-

Net decrease in cash, cash equivalents and restricted cash

-

-

-

-4,960

-7,777

12,348

-6,874

-6,705

8,751

1,712

-15,380

Interest paid

-

-

-

0

-

-

-

-

-

-

-

Supplemental disclosure of non-cash information:
Interest paid

7

19

116

-

-

-

-

-

-

-

-

Supplemental Disclosure of Non-cash Information:
Stock offering costs remaining in accounts payable and accrued expenses

-

-

221

0

-

-

-

-

-

-

-

Deemed dividend related to Series A Convertible Preferred Stock beneficial conversion feature

-

-

1,427

0

-

-

-

-

-

-

-

Preferred stock conversion to common stock

-

-

-

-

-

12,500

0

0

-

-

-

Purchase of property and equipment included in accounts payable and accrued expenses

-

-

-

-

68

0

0

-

-

-

-

Right-of-use assets acquired in exchange for lease liabilities

0

194

-

-

-

-

-

-

-

-

-

Lease incentive paid by lessor

-

-

-

1,332

0

-

-

-

-

-

-

Issuance of stock in connection with Aspire agreement

-

-

-

-

450

-

-

-

-

-

-

Restricted stock units issued to settle incentive compensation obligation

-

-

-

-

305

0

0

-

-

-

-

Transfer of equipment to settle contractual liability

-

-

-

111

0

-

-

-

-

-

-

Issuance of common stock to settle contractual liability

-

-

-

85

0

0

0

-

-

-

-